Imetelstat

Vivo Capital has closed the third cycle of its Opportunity Fund with over $740 million in commitments, focusing on preclinical and clinical-stage life sciences companies developing novel therapies.

New analyses from IMerge Phase 3 trial demonstrate imetelstat's efficacy in lower-risk MDS patients, showing consistent clinical activity regardless of prior treatment history.

Geron Corporation achieved $47.5 million in RYTELO (imetelstat) net product revenue in Q4 2024 and $76.5 million since its commercial launch in June 2024, following FDA approval for lower-risk myelodysplastic syndromes.

The FDA approved Madrigal's Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a significant unmet need in liver disease.

The European Commission has granted marketing authorization for imetelstat (Rytelo) as the first telomerase inhibitor approved for transfusion-dependent anemia in lower-risk myelodysplastic syndrome patients ineligible for or unresponsive to erythropoietin-based therapy.